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Background: Stenotrophomonas maltophilia is one of the most common multi-drug resistant organisms causing pulmonary infections in CF
patients. It is unknown whether S. maltophilia infection follows the same pattern and shares similar risk factors for acquisition as described for
Pseudomonas aeruginosa.
Methods: We examined all clinical events from 1997 to 2008 in the Toronto CF Database to identify risk factors for the acquisition
of S. maltophilia and to deﬁne distinct patterns of infection.
Results:We followed 601 patients over 12 years, during which time one quarter of subjects had at least one positive culture for S. maltophilia; the
incidence rate was slightly higher in children (11.6/100 person years) compared with adults (10.6/100 person years). Using multi-variable Cox
proportional hazards models, steeper rate of FEV1 decline was a signiﬁcant risk factor for S. maltophilia acquisition, whereas new infections were
less likely to occur with greater oral antibiotic use and a history of Burkholderia cepacia complex infection.
Conclusions: This study illustrates the evolution of S. maltophilia infection over time in a large cohort of adults and children with CF. Younger CF
patients, and those with greater lung function decline were at increased risk of S. maltophilia infection. The use of oral antibiotics to maintain lung
function may be a way of decreasing the risk of infection. However, the optimal management of CF patients with persistent S. maltophilia infection
is not yet known and requires further studies.
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Despite improvements in survival over the past 20 years, the
primary cause of death in CF is still respiratory failure secondary
to chronic bacterial respiratory infection [1]. Stenotrophomonas
maltophilia is one of the most common multi-drug resistant
organisms causing pulmonary infections in CF patients [2,3]. We
have recently demonstrated that chronic, but not intermittent,by Elsevier B.V. All rights reserved.
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specific systemic immune response to S. maltophilia and is an
independent risk factor for hospitalization for pulmonary
exacerbation [4]. The distinction between chronic and intermit-
tent infection is important for other pathogens in CF as well;
studies have shown that chronic methicillin-resistant Staphylo-
coccus aureus (MRSA) and Aspergillus fumigatus infections are
associated with clinical deterioration in CF patients [5,6].
To date, the evolution of airway infections with bacteria
other than Pseudomonas aeruginosa is largely unknown. In the
case of P. aeruginosa, CF patients are typically colonized with
non-mucoid P. aeruginosa initially and if untreated, eventually
develop chronic, mucoid P. aeruginosa infection that is very
difficult to eradicate and is associated with clinical decline [7].
Risk factors for the development of mucoid P. aeruginosa
infection in CF patients include female gender, number of delta
F508 alleles, decreased lung function and lack of S. aureus on
sputum culture [8]. Whether S. maltophilia infection follows
the same pattern as described for P. aeruginosa and shares
similar risk factors remains to be defined.
S. maltophilia infection is often considered to affect primarily
older CF patients with more advanced lung disease [9]. However,
recent studies describing high rates of S. maltophilia infection in
pediatric CF patients highlight our lack of knowledge of this
infection in the younger population [10]. Previous studies
examining risk factors for S. maltophilia have found antibiotic
use and poorer clinical status to be significantly associated with the
presence of infection [6,11–13]. These previous studies have been
limited to retrospective study designs where subjects were
classified as ever positive for S. maltophilia infection, which
may miss the complexity related to the acquisition of first
infection, or subsequent infection patterns. Furthermore, it is also
unclear whether current antimicrobial treatment directed against
S. maltophilia alters the course of S. maltophilia infection in CF
[6,11–13].
The aims of this study were thus to 1) determine the risk
factors for initial acquisition of S. maltophilia, 2) characterize
the patterns of S. maltophilia infection and 3) determine how
clinical outcomes differ between the groups identified.2. Materials and methods
2.1. Subject population and data collection
Pediatric and adult CF patients followed at Toronto CF
clinics from 1997 to 2008 were included in the study (n = 751).
Data were collected from the Toronto Cystic Fibrosis Database
as previously described [14]. Patients were excluded if they
were too young to perform spirometry (n = 38), if they were
unable to produce sputum (approximately 9% of microbiology
samples were excluded) or if they had received a lung
transplant (n = 88). Subjects with a positive culture prior to
1997 were excluded for these analyses (n = 24). This study was
approved by the Research Ethics Board at the Hospital for
Sick Children (REB# 1000013759) and St Michael's Hospital
(REB# 09-087c).2.2. Definitions of variables
Antibiotic therapy for S. maltophilia was defined as the
use of antibiotics with activity against S. maltophilia, such as
trimethoprim–sulfamethoxazole, levofloxacin, ticarcillin–
clavulanate and doxycycline [15,16]. Antibiotic use was
divided into terciles of cumulative number of courses of
1) non-ciprofloxacin oral antibiotics, 2) oral ciprofloxacin, and
3) intravenous antibiotics. Inhaled antibiotics were classified
as 1) never, 2) intermittent and 3) chronic, and defined as more
than 365 consecutive days of treatment. In adults body mass
index (BMI) was categorized as normal (BMI N 18 and ≤25),
underweight (BMI ≤ 18) and overweight (BMI N 25); in
children, BMI centiles were calculated based on the CDC
2000 reference charts, underweight was defined as a BMI
centile ≤ 12, normal (BMI centile N 12 and b85) and overweight
(BMI centile ≥ 85). Forced expiratory volume in 1 s (FEV1)
values were corrected for height, age and sex and analyzed as
percent predicted and z-scores [17]. Thereafter FEV1 was
summarized as 1) baseline visit (i.e. first visit after January 1,
1997), 2) FEV1 at the time of initial S. maltophilia acquisition
and 3) the rate of FEV1 change over the observation period
determined for each subject. For patients with positive
S. maltophilia cultures, the rate of decline was calculated
for the period before the acquisition of S. maltophilia (baseline to
first positive culture) and for the period after acquisition (first
positive culture to end of follow-up period). A pulmonary
exacerbation was defined, previously, as a hospitalization for
respiratory symptoms requiring intravenous antibiotics [4].
Previous infection with P. aeruginosawas classified according
to the Leeds criteria (never, ≤50% of cultures/year and N50%
of cultures positive/year). Burkholderia cepacia complex,
Haemophilus influenzae, S. aureus and Aspergillus (identified
as a risk factor for S. maltophilia acquisition in previous
studies [6]) infections were classified as ever positive based on
any positive culture prior to the first culture of S. maltophilia or
the last follow-up date. MRSA infection was not included due
to its low prevalence in the CF population in Canada and in our
center [18,19]. All microbiology data was based on culture
results from sputum or bronchoalveolar lavage samples.
2.3. Statistical analysis
Baseline characteristics were compared using non-parametric
t-test (Mann–Whitney) for continuous variables and chi square
test for categorical variables. Baseline characteristics for the
cohort were defined from each subject's first year of observation.
Cox proportional hazards survival models were used to identify
univariable risk factors for initial S. maltophilia infection during
the 12 year observation period. Subsequently, multivariable Cox
proportional hazards survival models were fitted for any risk
factors found to be significant or marginally significant on
univariable analysis (P b 0.15) and those with strong a priori
hypothesis (e.g. age, sex) for the same time period. A step-wise
approach was used to calculate hazard ratios (HR), with 95%
confidence intervals (CI), for the time to first respiratory specimen
(sputum or bronchoalveolar lavage sample) positive for S.
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covariates, whereas all other risk factors were time independent.
To classify sub-groups based on patterns of infection, the
cohort was first subdivided into ‘Ever’ and ‘Never’ S. maltophilia.
We then used latent class analysis to classify the ‘Ever’ group into
groups based on patterns of positive or negative cultures over time
following the initial positive culture [20]. We sequentially fit a 2,
3, 4, 5 and 6 class model based on up to 50 repeated cultures from
all 150 subjects with a history of S. maltophilia. The model with
the best fit was determined using the Schwartz Bayesian Criteria.
Each subject with a history of S. maltophilia infection was then
classified according to the probability of belonging to an infection
pattern category.
Finally, we compared clinical characteristics based on the
newly defined infection patterns. Differences between groups
were compared using a Kruskall–Wallis test non-parametric
data. Statistical analysis was performed using STATA (version
11.0) and the poLCA package in R (CRAN project).
3. Results
3.1. Baseline patient characteristics
Between 1997 and 2008, 601 patients (without a positive
culture for S. maltophilia prior to 1997) were followed at
The Hospital for Sick Children and St Michael's Hospital,
Toronto. During the twelve-year observation period, 25.1% of
the patient population (n = 151) had at least one positive
respiratory tract culture for S. maltophilia; an incidence rate of
11.2/100 person years. The incidence rate was slightly higher
in children (11.6/100 person years) less than 18 years of age
compared with adults (10.6/100 person years). The baseline
characteristics of the entire cohort, those with at least one
positive S. maltophilia culture (Ever) and those without (Never)
are summarized in Table 1. The median length of follow-up
was 9.2 years (interquartile range 4.0–11.6); patients who were
ever positive for S. maltophilia were younger upon entry into
the cohort (median 10 years of age) and were followed for
longer (median 11 years). Subjects with S. maltophilia were
less likely to have P. aeruginosa or B. cepacia complex
infection prior to their first infection. They were also less likely
to have been infected with Aspergillus. Baseline FEV1 did not
differ between the two groups, but the rate of FEV1 decline
prior to the first acquisition of S. maltophilia was greater in
the group with S. maltophilia. In addition, use of oral and
intravenous antibiotics was less frequent in patients with
S. maltophilia infection compared to the group without
S. maltophilia infection (Table 1).
3.2. Factors associated with increased or decreased risk of
S. maltophilia infection
Risk factors to the time to first infection with S. maltophilia
were initially identified using a univariable Cox proportional
hazards model (Table 2, Fig. 1). With increasing age, the risk of
S. maltophilia infection decreased; for each year increase in
age, the risk of S. maltophilia decreased by 2% (HR 0.98, 95%CI 0.97–1.00). Subjects who were chronically infected with
P. aeruginosa or had B. cepacia complex, or Aspergillus
infection were less likely to acquire S. maltophilia. A greater
decline in FEV1 was associated with an increased risk of
S. maltophilia infection. In addition, greater oral antibiotic use
(ciprofloxacin and non-ciprofloxacin) was associated with less
S. maltophilia infection.
A multi-variable Cox proportional hazards model (Table 3,
Fig. 2) was developed including variables found to be significant
on univariable analysis (age, baseline FEV1, rate of FEV1 decline,
BMI, non-ciprofloxacin antibiotics, ciprofloxacin antibiotics, IV
antibiotics, B. cepacia complex, P. aeruginosa and Aspergillus
infection). A steeper rate of FEV1 decline remained a significant
risk factor for S. maltophilia acquisition. S. maltophilia was less
likely to occur in older subjects, and when oral antibiotics were
used. There was a clear gradient observed with antibiotic use, that
is, more antibiotics resulted in smaller hazard ratios for
S. maltophilia. Replacing antibiotics with P. aeruginosa infec-
tion, to avoid confounding by indication, P. aeruginosa was also
an independent and significant predictor of S. maltophilia, where
chronic infection with P. aeruginosa was associated with a lower
risk of S. maltophilia (chronic HR 0.57 (95% CI 0.34; 0.89)).
S. maltophilia was also less likely if subjects had a positive
history for B. cepacia complex. The models for children and
adults were similar, with B. cepacia complex only remaining
significant in the adult model. Post-hoc examination of the burden
of infection (number of positive culture for S. aureus and
H. influenzae) was not associated with the courses of antibiotics.
The rate of FEV1 decline was slower with increased use of oral
antibiotics.
3.3. Patterns of S. maltophilia infection and associated clinical
outcomes
Using latent class analysis for subjects with a history of
S. maltophilia, we identified three distinct patterns of positive
cultures after first infection; 1) Persistent, where the majority of
cultures were positive, 2) Rare, where positive cultures were
rare (negative for the majority of cultures, up to a maximum of
1 positive culture per year), and 3) Cleared, where after a series
of positive cultures, patients seldom had a subsequent positive
culture (Fig. 3).
Subsequently, each subject was assigned to one of four
groups (Never, Persistent, Rare and Cleared) based on the
frequency of their positive S. maltophilia cultures (Table 4).
The Rare group was most common (61%) followed by the
Cleared (26%) and the Persistent group (13%). Clinical
outcomes were compared for the period following the initial
positive S. maltophilia culture. The rate of lung function
decline differed between the groups, with the steepest decline
observed in the ‘Cleared’ group. Patients with persistent
S. maltophilia infection had the highest number of pulmonary
exacerbations following initial infection, and the greatest
number of intravenous antibiotic courses. Those with persistent
S. maltophilia had the most antibiotic courses directed against
S. maltophilia infection, significantly more than the Cleared
group. In a separate analysis comparing antibiotic use in the
Table 1
Baseline patient characteristics stratified by S. maltophilia infection status.
Total
n = 601
Never
S. maltophilia
n = 450
Ever
S. maltophilia
n = 151
P value
Median follow-up time (years) (IQR) 9.2 (4.0; 11.6) 8.8 (3.5; 11.5) 10.7 (6.5; 11.7) b0.001
Median age (years) (IQR) 11.97 (4.5; 23.8) 13.7 (4.9; 23.9) 9.6 (4.2; 21.4) 0.008
Female, n (%) 268 (44.6) 199 (44.2) 69 (45.7) 0.753
Age at CF diagnosis (%)
b1 year 331 (55.1) 240 (53.3) 91 (60.3) 0.463
b12 years 185 (30.8) 145 (32.2) 40 (26.5)
b18 years 34 (5.7) 25 (5.6) 9 (6.0)
≥18 years 51 (8.5) 40 (8.9) 11 (7.3)
Genotype, n (%)
Homozygous ΔF508 253 (42.1) 183 (40.7) 70 (46.4) 0.412
Heterozygous ΔF508 231 (38.4) 174 (38.7) 57 (37.8)
Other/other 74 (12.3) 59 (13.1) 15 (9.9)
Unknown 43 (7.2) 34 (7.6) 9 (6.0)
Pancreatic status, n (%)
Insufficient 492 (81.9) 361 (80.4) 129 (86.0) 0.119
Sufficient 109 (18.1) 88 (19.6) 21 (13.9)
CF related diabetes mellitus, n (%) 92 (15.3) 61 (13.6) 31 (20.5) 0.049
Body mass index, n (%)
Underweight 73 (12.5) 50 (11.1) 23 (15.2) 0.283
Normal weight 408 (67.9) 304 (67.6) 104 (68.9)
Overweight 92 (14.6) 73 (16.2) 19 (12.6)
Missing 28 (4.7) 23 (5.1) 5 (3.3)
P. aeruginosa infection, n (%)
Never 160 (26.6) 110 (24.4) 50 (33.1) 0.006
Intermittent 49 (8.2) 31 (6.9) 18 (11.9)
Chronic 270 (44.9) 216 (48.0) 54 (35.8)
Unknown 122 (20.3) 93 (20.7) 29 (19.2)
B. cepacia complex infection, n (%) 90 (15.0) 77 (17.1) 13 (8.6) 0.008
S. aureus infection, n (%) 376 (62.6) 276 (61.3) 100 (66.2) 0.280
H. influenzae infection, n (%) 301 (50.1) 221 (49.1) 80 (52.9) 0.469
Aspergillus infection, n (%) 185 (30.9) 154 (34.3) 31 (20.7) 0.001
Any pulmonary exacerbation, n (%) 393 (65.4) 300 (66.7) 93 (61.6) 0.256
Lung function
Mean ΔFEV1 % predicted/year (SD) −1.1 (3.0) −0.9 (2.7) −1.8 (3.7) 0.013
Baseline lung function (% predicted) mean (SD) 76.3 (22.5) 76.7 (22.4) 75.0 (22.9) 0.357
Lung function (% predicted) at time of S. maltophilia acquisition N/A N/A 64.8 (21.0) N/A
Non-ciprofloxacin oral antibiotic use
Lowest tercile 249 (41.4) 165 (36.7) 84 (55.6) b0.001
Middle tercile 213 (35.4) 173 (38.4) 40 (26.5)
Highest tercile 139 (23.1) 112 (24.9) 27 (17.9)
Ciprofloxacin oral antibiotic use
Lowest tercile 243 (40.4) 170 (37.8) 73 (48.3) 0.004
Middle tercile 212 (35.3) 156 (34.7) 56 (37.1)
Highest tercile 146 (24.3) 124 (27.6) 22 (14.6)
Inhaled antibiotic use
None 166 (27.6) 128 (28.4) 38 (25.2) 0.403
Intermittent 109 (18.1) 85 (18.9) 24 (15.9)
Chronic (N365 consecutive days) 326 (54.2) 237 (52.7) 89 (58.9)
IV antibiotic use
Lowest tercile 282 (46.9) 211 (46.9) 71 (47.0) 0.024
Middle tercile 207 (34.4) 145 (32.2) 62 (41.1)
Highest tercile 112 (18.6) 94 (20.9) 18 (11.9)
FEV1: forced expiratory volume in 1 s.
IQR: interquartile range.
N/A: not applicable.
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Table 2
Univariable Cox proportional hazards model for time to first S. maltophilia infection.
Pediatric (≤18 years) Adults (N18 years)
n = 379 HR (95% CI) n = 222 HR (95% CI)
Increasing age (years) – 0.97 (0.90; 1.05) – 1.00 (0.97; 1.02)
Female 185 0.91 (0.56; 1.47) 83 1.34 (0.79; 2.25)
Age at diagnosis
b1 year 247 1.0 84 1.0
b12 years 120 0.80 (0.47; 1.38) 65 0.89 (0.47; 1.68)
b18 years 12 2.66 (0.63; 11.18) 22 1.46 (0.63; 3.38)
≥18 years N/A N/A 51 1.13 (0.52; 2.44)
Genotype
Homozygous ΔF508 174 1.0 79 1.0
Heterozygous ΔF508 140 0.78 (0.47; 1.32) 91 1.18 (0.67; 2.10)
Other/other 41 1.07 (0.49; 2.41) 33 0.63 (0.24; 1.68)
Pancreatic insufficient 344 2.55 (0.80; 8.13) 148 0.86 (0.47; 1.56)
CF related diabetes mellitus 42 1.26 (0.63; 2.55) 50 1.51 (0.88; 2.61)
Body mass index category
Normal weight 63 1.0 10 1.0
Underweight 247 0.75 (0.43; 1.33) 161 0.56 (0.20; 1.57)
Overweight 43 0.29 (0.08; 0.99) 49 0.44 (0.14; 1.41)
P. aeruginosa infection
Never 97 1.0 63 1.0
Intermittent 35 0.95 (0.44; 2.03) 14 1.51 (0.62; 3.70)
Chronic 127 0.70 (0.38; 1.27) 143 0.57 (0.31; 1.01)
B. cepacia complex infection 17 0.39 (0.05; 2.84) 73 0.51 (0.27; 0.97)
S. aureus infection 67 0.75 (0.37; 1.54) 29 1.14 (0.58; 2.27)
H. influenzae infection 51 0.97 (0.57; 1.68) 33 0.87 (0.48; 1.57)
Aspergillus infection 45 ** 109 0.65 (0.39; 1.10)
Any pulmonary exacerbation 250 0.60 (0.37; 0.97) 143 1.34 (0.74; 2.42)
(log)Time to first exacerbation – 0.90 (0.72; 1.12) – 0.86 (0.72; 1.02)
Lung function
Rate of FEV1 decline (% pred/year) – 1.11 (1.00; 1.24) – 1.17 (1.01; 1.35)
Baseline lung function – 0.99 (0.98; 1.0) – 0.99 (0.98; 1.00)
FEV1 % predicted – 0.98 (0.97; 0.99) – 0.98 (0.97; 1.0)
Non-ciprofloxacin oral antibiotic use
Lowest tercile 136 1.0 113 1.0
Middle tercile 166 0.25 (0.14; 0.42) 47 0.34 (0.17; 0.70)
Highest tercile 77 0.20 (0.09; 0.42) 62 0.51 (0.27; 0.96)
Ciprofloxacin oral antibiotic use
Lowest tercile 191 1.0 52 1.0
Middle tercile 131 0.83 (0.51; 1.34) 81 0.59 (0.31; 1.15)
Highest tercile 57 0.07 (0.01; 0.48) 89 0.39 (0.20; 0.76)
Inhaled antibiotic use
None 103 1.0 63 1.0
Chronic (N365 consecutive days) 197 1.61 (0.79; 3.29) 129 0.94 (0.49; 1.82)
Intermittent 79 1.69 (0.73; 3.91) 30 0.90 (0.34; 2.40)
IV antibiotic use
Lowest tercile 184 1.0 98 1.0
Middle tercile 150 1.19 (0.73; 1.94) 67 1.63 (0.92; 2.91)
Highest tercile 55 0.45 (0.18; 1.15) 57 0.65 (0.30; 1.37)
FEV1: forced expiratory volume in 1 s.
HR: hazard ratio.
CI: confidence interval.
**: too few observations in the pediatric group to estimate hazard ratio appropriately.
N/A: not applicable due to no observations.
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Fig. 1. Forest plot of the univariable Cox proportional hazards model for time to first S. maltophilia infection. The center indicates the HR with 95% confidence
intervals.
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the Cleared group did not have more anti-S. maltophilia
antibiotics compared to the Persistent group.Table 3
Multivariable Cox proportional hazards model for time to first S. maltophilia
infection.
Total, n = 601
HR (95% CI)
≤18 years,
n = 379
HR (95% CI)
>18 years,
n = 222
HR (95% CI)
Increasing age 0.98 (0.96; 1.00) 0.83 (0.74; 0.93) 0.99 (0.96; 1.02)
Baseline FEV1 0.98 (0.97; 0.99) 0.98 (0.96; 0.99) 0.98 (0.97; 1.0)
Rate of FEV1 decline 1.18 (1.10; 1.26) 1.17 (1.07; 1.26) 1.20 (1.05; 1.37)
Non-ciprofloxacin antibiotics
Lowest tercile 1.0 1.0 1.0
Middle tercile 0.34 (0.21; 0.56) 0.18 (0.09; 0.34) 0.41 (0.19; 0.88)
Highest tercile 0.51 (0.30; 0.86) 0.14 (0.06; 0.31) 0.75 (0.37; 1.54)
Ciprofloxacin antibiotics
Lowest tercile 1.0 1.0 1.0
Middle tercile 0.60 (0.39; 0.95) 0.84 (0.50; 1.42) 0.60 (0.29; 1.22)
Highest tercile 0.29 (0.16; 0.50) 0.06 (0.01; 0.50) 0.40 (0.19; 0.83)
B. cepacia infection 0.49 (0.26; 0.90) 0.51 (0.26; 1.02)
FEV1: forced expiratory volume in 1 s.
HR: hazard ratio.
CI: confidence intervals.
Age and baseline FEV1 were included in each model, but only displayed when
the variable contributed significantly to the model.4. Discussion
This is the first study to investigate the evolution of
S. maltophilia infection in a large cohort of pediatric and
adult CF patients followed over a period of 12 years. We
identified that younger patients and those with a steeper rate of
lung function decline were at increased risk of S. maltophilia
infection. In contrast to previous studies, we also demonstrated
that greater oral antibiotic use was associated with a decreased
risk of S. maltophilia acquisition.
Previous studies that have investigated risk factors for
S. maltophilia infection in CF patients have been limited to
cross-sectional data, where risk factors were classified based on
observations at one point in time. These original case control
studies demonstrated that CF patients with worse clinical
outcomes, including worse nutritional parameters and lung
function, were more likely to be infected with S. maltophilia
[13]. Our investigations also demonstrated that patients with
steeper rates of FEV1 decline were at increased risk of acquiring
S. maltophilia infection. Retrospective case control studies also
suggested that increased antibiotic use (intravenous, oral or
inhaled) was more common in CF individuals with S. maltophilia
[6,11,12]; however, due to their cross-sectional nature, these
studies were not able to determinewhether antibiotic use preceded
S. maltophilia infection. In addition, retrospective analysis of
randomized, placebo-controlled trials of inhaled tobramycin
showed that oral ciprofloxacin (but not inhaled tobramycin) was
Fig. 2. Forest plot of multivariable Cox proportional hazards model for time to first S. maltophilia infection. The center indicates the HR with 95% confidence
intervals.
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this study was conducted solely in adult CF patients with chronic
P. aeruginosa endobronchial infections [12]. Based on these
retrospective studies, it was assumed that antibiotic use was
selecting out multi-drug resistant pathogens and was thus a risk
factor for S. maltophilia in CF.
Our study has the advantage of being a large cohort of both
pediatric and adult CF patients followed longitudinally over a
12 year period with detailed antibiotic data with respect to theFig. 3. Latent class analysis was used to define categories of S. maltophilia
infection patterns based on multiple culture results over time. We sequentially
fit a 2, 3, 4, 5 and 6 class model based on up to 50 repeated cultures from all 165
subjects with a history of S. maltophilia. The model with the best fit was
determined using the Schwartz Bayesian Criteria. We identified 3 groups: a
Persistent, a Cleared and a Rare group.type, mode of delivery and duration of antibiotic therapy. Using
this study design, we were able to demonstrate the novel finding
that greater use of oral antibiotics, including ciprofloxacin and
anti-Staphylococcal antibiotics such as cephalexin and cloxa-
cillin, was not a risk factor for S. maltophilia infection but
reduced the risk of infection. There are several possible
explanations for why oral antibiotic use is associated with a
decreased risk of S. maltophilia acquisition. Oral antibiotic use
may reflect a physician's response to organisms identified in
sputum culture results. However, in this study, we did not
observe an association between increased antibiotic use and
greater number of S. maltophilia positive cultures. Another
possible explanation is that oral antibiotic use is a proxy for mild
exacerbations. Although our dataset did not include signs and
symptoms of respiratory deterioration, it did include detailed
lung function measurements, which demonstrated a slower rate
of FEV1 decline with greater oral antibiotic use. Although we
cannot demonstrate causality in this study, oral antibiotic
treatment may help to maintain lung function, which was the
most consistent risk factor for S. maltophilia infection. This is
also consistent with previous studies, which have suggested that
non-quinolone oral antibiotics are associated with overall better
lung function in CF patients [21]. It is possible that our study
population was biased with predominantly younger CF patients
(60% positive before 18 years of age), in whom oral antibiotics
may have a greater effect, rather than older patients with
end-stage lung disease. In addition, our study may also have
been biased toward the sicker children as we excluded those too
young to perform spirometry or produce sputum (typically
b6 years of age). This is an important observation for clinicians,
as previously there has been reluctance to treat CF patients with
oral antibiotics due to the risk of selecting out multi-drug
resistant pathogens such as S. maltophilia. Antibiotic therapy
may actually be protective against acquisition of S. maltophilia
Table 4
Clinical outcomes following first positive S. maltophilia culture based on infection patterns.
Never
(n = 492)
Rare
(n = 97)
Cleared
(n = 45)
Persistent
(n = 23)
P value
Age at first S. maltophilia infection, median (IQR) N/A 16.9 (11.1; 27.1) 14.3 (12.1; 21.9) 14.7 (11.7; 31.0) b0.001
Δ in FEV1 % pred/year, median (IQR) −1.37 (−2.55; −0.14) −0.68 (−3.07; 0.35) −2.16 (−4.67; 1.77) −1.25 (−3.74; 0.22) b0.001
No. of pulmonary exacerbations/year, median (IQR) 0 (0;1) 0 (0;1) 0 (0;1) 1 (0;2) b0.001
Antibiotic use
No. of S. maltophilia antibiotic courses/year, median (IQR) 0 0 (0;2) 1 (1;3) 5 (3;12) b0.001
No. of non-ciprofloxacin courses/year, median (IQR) 7 (4;12) 0 (0;7) 0 (0;4) 5 (0;10) b0.001
No. of ciprofloxacin courses/year, median (IQR) 3 (0;8) 0 (0;2) 0 (0;2) 1 (0;6) b0.001
No. of inhaled antibiotic courses/year, median (IQR) 2 (1;3) 0 (0;1) 0 (0;1) 0 (0;2) b0.001
No. of intravenous antibiotic courses/year, median (IQR) 1 (1;6) 0 (0;2) 0 (0;2) 3 (0;8) b0.001
N/A: not applicable.
FEV1: forced expiratory volume in 1 s.
IQR: interquartile range.
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datasets is needed.
Chronic P. aeruginosa, B. cepacia complex and Aspergillus
infections were also noted to be associated with a decreased risk
of S. maltophilia infection in our study. These findings likely
reflect the CF lung microbiome, which in these cases may be
dominated by other species. For example, it was previously
observed that S. aureus colonization protected against mucoid
P. aeruginosa infection [8]. Ongoing longitudinal analyses of
the CF lung microbiome using culture independent techniques
may further inform about the evolution of these infections over
time.
This study also used the novel approach of latent class analysis
to characterize the patterns of infection with S. maltophilia.
Previous definitions of chronic and intermittent infections have
relied on the Leeds criteria; although these definitions did
correlate with clinical status, the criteria are limited to microbi-
ological data obtained in the previous 12 months and necessitate a
minimum number of cultures per year [22]. Latent class analysis
has been used to characterize complex respiratory and allergic
illnesses such as asthma [23] into distinct phenotypes creating
patterns of association in the symptoms. Such a methodology can
also be used to describe S. maltophilia infection in CF patients, a
complex disease which changes over time and is likely influenced
by factors such as antimicrobial therapy. Whereas the Leeds
criteria provide a snapshot of an individual's infection history,
latent class analysis offers a wider observation window. Using
latent class analysis, we were able to confirm our previous finding
that CF patients with persistent S. maltophilia infection have more
pulmonary exacerbations, and thus more intravenous antibiotic
courses, than patients who do not have persistent infection but not
a more rapid rate of FEV1 decline [4]. It is not known whether
these intravenous antibiotic courses protect against subsequent
lung function deterioration. In addition, we demonstrated that only
a minority of patients will go on to develop persistent infection.
Although it is unclear if early antibiotic intervention has an effect
on the development of such patterns, analysis of the antibiotic use
in the first year following the initial S. maltophilia infection did
not show the Cleared group to have more anti-S. maltophilia
antibiotic courses.One of the main strengths of this study was that we examined
the risk factors for the acquisition of S. maltophilia by using a
longitudinal time to event analysis. In addition, the Toronto CF
population is the largest CF population in Canada. While the
dataset was comprehensive and included all clinic events in
the observation period, it is possible that several confounders,
including disease severity and concomitant infections may be
causally related and thus provides alternative explanations to our
observations. Our classifications of S. maltophilia types are based
on a large dataset of microbiological cultures taken over a period
of 12 years and an objective approach that selected patterns of
infection based on the model with the best fit. A longer follow-up
of this cohort is required to determine whether the patients change
groups, whether the infections are truly cleared or whether there
is simply a longer lag time before re-infection. It is not clear,
for example, why patients who apparently clear S. maltophilia
infection have the steepest rate of lung function decline; it is
possible that in this context S. maltophilia infection is merely an
epiphenomenon.
In conclusion, this study illustrates the evolution of
S. maltophilia infection over time in a large cohort of
adults and children with CF. Younger CF patients, and
those with greater lung function decline are at increased risk of
S. maltophilia infection. The use of oral antibiotics to maintain
lung function may be a way of decreasing the risk of infection.
Only a minority of patients will go on to develop persistent
infection, which is associated with increased pulmonary exacer-
bations and intravenous antibiotic use. The optimal management
of such high-risk CF patients with persistent S. maltophilia
infection is not yet known and requires the conduct of prospective
interventional studies.Conﬂict of interest
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